MANAGEMENT OF COVID ASSOCIATED ORBITAL MUCORMYCOSIS IN TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i11.45339Keywords:
COVID-19 associated mucormucosis, Orbital mucormycosis, Diabetes mellitus in mucormycosis, Corticosteroids in mucormycosis, Management of mucormycosisAbstract
Objectives: The aim of the study was to study epidemiological characteristics and management of orbital mucormycosis in cases of rhino-orbital mucormycosis in tertiary care hospital.
Methods: It is a retrospective study of 258 patients presenting to KGH, Visakhapatnam, over a duration of 3 months from June to August 2021. After taking detailed history regarding symptoms of mucormycosis, visual acuity was noted, slit lamp examination was done and necessary investigations such as microbiology, pathology specimens were sent and analyzed, imaging done, and management done accordingly.
Results: The majority of patients came with ENT-related symptoms were treated with endoscopic debridement, that is, 216 (84%), endoscopic debridement with orbital decompression of 23 (9%), transcutaneous retrobulbar amphotericin B of 21 (8%), orbital exenteration of 17 (6.5%), total and partial maxillectomy of 28 (10.8%), temporal lobe abscess drainage of 7 (2.7%), frontal lobe abscess drainage of (1.16%), frontal bone abscess drainage of 3 (1.16%), dural abscess drainage of 6 (2.3%), 15 (5.8) treated conservatively, and 30 (11.6%) death.
Conclusion: COVID-19 infection in presence of glycemic dysregulation predisposes to development of Rhino-orbital-cerebral mucormycosis. Strict glycemic control and judicious use of corticosteroids might help in decrease incidence of mucormycosis cases. Most of the patients presents with ENT-related symptoms if not treated early may spread to orbit and intracranial sites. Early treatment during early presentation might help prevent spreading orbital extension and intracranial extension.
Downloads
References
Arora R, Goel R, Khanam S, Kumar S, Shah S, Singh S, et al. Rhino-orbito-cerebral-mucormycosis during the COVID-19 second wave in 2021-A preliminary report from a single hospital. Clin Ophthalmol 2021;15:3505-14. doi: 10.2147/OPTH.S324977, PMID 34429582, PMCID PMC8380130
Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID- 19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India-collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021;69:1670-92. doi: 10.4103/ijo.IJO_1565_21, PMID 34156034, PMCID PMC8374756
Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, et al. COVID-19-associated mucormycosis presenting to the emergency department-an observational study of 70 patients. QJM 2021;114:464-70. doi: 10.1093/qjmed/hcab190, PMID 34254132, PMCID PMC8420631
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146. doi: 10.1016/j.dsx.2021.05.019. PMID 34192610, PMCID PMC8137376
Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses 2021;64:1238-52. doi: 10.1111/myc.13334, PMID 34096653
Honavar SG. Code mucor: Guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021;69:1361-5. doi: 10.4103/ijo. IJO_1165_21, PMID 34011699
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601-15. doi: 10.1038/s41591-021-01283-z, PMID 33753937
Published
How to Cite
Issue
Section
Copyright (c) 2022 Bhavya sri sai Vejendla
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
